LATITUDE Study Articles


  • Another Advance in Metastatic Hormone-Sensitive Prostate Cancer May Change Standard of Care Options but Not Attitude Toward Clinical Trials

    For the longest time metastatic hormone-sensitive prostate cancer has been treated with androgen deprivation therapy (ADT).  Recently, the CHAARTED1 trial and STAMPEDE,2 both showed a dramatic survival benefit when 6 cycles of docetaxel was added to ADT.  For the CHAARTED trial, subgroup analyses confirmed survival benefit for those patients with high volume disease, defined as ≥4 bone metastases with at least one in the appendicular skeleton and/or a visceral metastasis. 
    Published July 14, 2017
  • Changes in Latitude, Changes in Attitudes… and DABGA

    I write today not from the files of the Jimmy Buffet musical collection, nor from a Caribbean Margaritaville-esque cabana, as the reference might suggest (for the unfamiliar, I have been humming his song “Changes in Latitude, Changes in Attitude…for about 2 weeks now)  but rather as a dispatch on the latest development in clinical trials in prostate cancer.  The topic:  Data from the Latitude study that was presented at ASCO by Karim Fizazi and simultaneously published in the New England Journal of Medicine.
    Published June 21, 2017
  • Crashing into Progress: New Findings Meet Old Habits

    In the last few weeks I have talked with numerous colleagues about the findings from LATITUDE and STAMPEDE presented recently at the ASCO Annual Meeting and published in the New England Journal of Medicine in June 2017.  We find ourselves in the process of integrating the findings into a treatment landscape that is still grappling with the findings of CHAARTED, data demonstrating a survival benefit from the use of chemohormonal therapy in a similar high risk population of men with metastatic hormone sensitive prostate cancer (mHSPC) first presented only a few years ago. 
    Published July 27, 2017
  • How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: A retrospective multicenter cohort study.

    Recent landmark randomized trials (CHAARTED and LATITUDE studies) have highlighted potent upfront therapy for "high-volume" and "high-risk" metastatic castration-naïve prostate cancer (mCNPC).

    Published February 18, 2020